TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02559284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A postoperative care after ethmoid sinus surgery
Description: A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~* Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~* Gentle blowing of the nose~* Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A postoperative care after ethmoid sinus surgery
Description: A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~* Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~* Gentle blowing of the nose~* Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing).
Study: NCT02578147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mighty Girls

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Game Girls
Study: NCT00656448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procrit
Description: 40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
Study: NCT04964180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin suppository
Description: two 100 mg indomethacin rectal suppositories 2 hours prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: 200 ml saline containing 200 mg 2%lidocaine intraperitoneal insilltation
Study: NCT01808456

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza trivalent inactive vaccine
Description: one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza trivalent inactive vaccine high dose
Description: one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
Study: NCT04071717

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIRS neurofeedback
Description: Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIRS neurofeedback
Description: Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham NIRS neurofeedback
Description: Sham NIRS neurofeedback
Study: NCT01981408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-LY2801653
Description: Administered orally
Study: NCT02877407

Intervention type: PROCEDURE
Group type: OTHER
Intervention: patient who undergo laparoscopic/robotic-assisted hysteropexy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: patient who undergo vaginal hysterectomy
Study: NCT00646048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriVascular Stent-Graft System
Description: TriVascular Stent-Graft System
Study: NCT01547611

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Customary treatment
Description: The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured behavioural medicine program
Description: The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
Study: NCT00863278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed dye laser treatment
Description: On one side of the face according to Arm placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed dye laser treatment
Description: On one side of the face according to Arm placement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kligman's Trio
Description: The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kligman's Trio
Description: The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
Study: NCT04591431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: TT arm
Study: NCT00432172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03968393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulant (NOAC)
Description: Participants randomized to the intervention arm will be prescribed one of the following NOACs for the duration of follow-up: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
Study: NCT00700479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldosterone
Description: 4 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldosterone
Description: 4 hour infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low or high sodium diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low or high sodium diet
Study: NCT04591431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: TT arm
Study: NCT00700479

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: low or high sodium diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: low or high sodium diet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02756286

Intervention type: OTHER
Intervention: NAT electroencephalography (EEG) test
Description: Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.

Intervention type: OTHER
Intervention: NAT electroencephalography (EEG) test
Description: Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
Study: NCT00305188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaliproden (SR57746A)
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV administration
Study: NCT00888173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib Alaninate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04514861

Intervention type: DEVICE
Group type: OTHER
Intervention: Wireless Lumee Oxygen Platform
Description: The Lumee Oxygen Platform is designed to monitor oxygen dynamics with a hydrogel placed in subcutaneous tissue
Study: NCT01113255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bench-evaluation, of three ventilators
Description: to select in-VITRO the most appropriate ventilator for a given pathology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bench-evaluation, of three ventilators
Description: to select in-VITRO the most appropriate ventilator for a given pathology.
Study: NCT03719079

Intervention type: DEVICE
Intervention: SimpleSENSE
Description: The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device
Study: NCT02939911

Intervention type: DEVICE
Intervention: Residual neuromuscular blockade measurement
Description: Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
Study: NCT02007096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transabdominal Plane Block
Description: 0.25% bupivacaine injection in 6 different locations in abdomen. Weight \<100kg: 50ml total; weight \>100kg: 60ml total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non Transabdominal Plane Block
Description: Saline injection in 6 different locations in abdomen. Weight \<100kg: 50ml; weight \>100kg: 60ml
Study: NCT04124809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser assisted collapse
Description: Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
Study: NCT02233686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-D0501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01752335

Intervention type: OTHER
Group type: OTHER
Intervention: Braquial ecography
Description: At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
Study: NCT04543708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision drainage
Description: Oropharyngeal pre-anesthesia is performed with 10% xylocaine spray, then submucosal anesthesia of the anterior pillar of the tonsil is performed with 2 ml of Rapidocaine or Rapidocaine 1 or 2% adrenaline. A scalpel incision is made with the search for the abscess pocket with a crile. If pus is present, a NaCl / Betadine rinse is performed. A syringe puncture can help locate the abscess if needed. The duration is approximately 15 minutes.~If no purulent pouch is found, the procedure is completed with tonsillectomy under general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Under general anesthesia, in dorsal decubitus, an autostatic mouth opener is placed, an incision of the anterior pillar of the tonsil allows the opening of the capsular space, along which the entire tonsil is dissected until complete extraction, hemostasis is performed, then the patient is awakened. The duration is approximately 30 minutes.
Study: NCT00630838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
Study: NCT05313971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self knowledge course
Description: The online self-knowledge and communication course, created for the purpose of this clinical trial and taught by professionals with certified training in the area by the Shalom Enneagram Institute (https://iesh.pt/), consisted of providing volunteers with mechanisms for self-knowledge using the enneagram. Three modules were carried out between October and December 2020, spaced in time to allow participants to consolidate knowledge: there was 1 month between the first and second module, and between the second and third, 3 weeks.
Study: NCT04551547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 300SU/0.5ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0,28
Description: The placebo contains no active ingredient and manufactured by Sinovac Research \& Development Co., Ltd.
Study: NCT03010215

Intervention type: OTHER
Group type: OTHER
Intervention: Distal Metatarsal Minimally invasive Osteotomy (DMMO)
Description: Percutaneous dorsal incision at the level of the the distal part of the metatarsal bone, a Shannon burr is introduced at the level of metatarsal neck, with orientation of at approximately 45°, keeping the articular cartilage surface of the metatarsal head as reference point on the superior cortex.~In this position, under fluoroscopic control, the osteotomy is started following a distal-dorsal and proximal-plantar direction. In this way the metatarsal head moves proximally and dorsally reducing the metatarsal pressure on the plantar ulcer.
Study: NCT04591431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismogedib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: TT arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oncology Drugs
Description: Standard of Care Arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: TT arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: TT arm
Study: NCT02070003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Physician Guided Opioid Weaning
Study: NCT00872820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance- and commitment-based behavioral therapy
Description: 12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: 12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
Study: NCT04537624

Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT04201262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.
Study: NCT03459755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise.
Study: NCT04006405

Intervention type: DIAGNOSTIC_TEST
Intervention: GAG score
Description: blood and urine samples to determine GAG scores

Intervention type: DIAGNOSTIC_TEST
Intervention: GAG score
Description: blood and urine samples to determine GAG scores
Study: NCT00794716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
Study: NCT01051895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high risk HPV DNA testing
Description: Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Routine colposcopy
Description: Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
Study: NCT03844750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Undergo liver resection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: Given orally